Evaxion A/S Sponsored ADR EVAX 深 滬
等待開盤 03-26 09:30:00 美东时间
3.70
+0.025
+0.68%
華盛通- 最 高4.00
- 今 開3.65
- 成交量 1.00万股
- 最 低 3.58
- 昨 收 3.675
- 總市值 3085.88万
- 52周最高 12.1499
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.20
- 委 比 99.59%
- 總股本 834.02万
- 歷史最高 1252.00
- 量 比 0.38
- 振 幅 11.43%
- 歷史最低 2.871
- 每 手 1
- 風險率 1.64%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅148%！瑞银、小摩等8家大行首予SOLV Energy买入评级目标价42美元；甲骨文绩前遭德银等下调目标价；京东遭巴克莱下调目标价
今日重点评级关注：Evercore ISI集团：维持Caribou Biosciences"跑赢大市"评级，目标价从11美元升至13美元；富国银行：上调uniQure评级至"超配"，目标价从15美元升至60美元
03-10 15:05
HC Wainwright & Co. Reiterates Buy on Evaxion, Maintains $16 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Evaxion (NASDAQ:EVAX) with a Buy and maintains $16 price target.
03-09 18:17
Evaxion Earnings Report: Q4 Overview
Evaxion (NASDAQ:EVAX) released its Q4 earnings on Thursday, March 5, 2026 at 09...
03-05 22:38
Evaxion Biotech Q4 EPS $(0.02) Beats $(0.30) Estimate
Evaxion Biotech (NASDAQ:EVAX) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.30) by 93.27 percent. This is a 90.48 percent increase over losses of $(0.21) per share from
03-05 22:35
Insights into Evaxion Q4 Earnings
Evaxion (NASDAQ:EVAX) reported its Q4 earnings results on Thursday, March 5, 20...
03-05 22:32
Earnings Scheduled For March 5, 2026
Companies Reporting Before The Bell • Palladyne AI (NASDAQ:PDYN) is projected t...
03-05 19:11
Evaxion Seeks New Partner For Gonorrhea Vaccine After Merck Opts Out
Merck declines its option on Evaxion's EVX-B2 gonorrhea vaccine, leaving global rights with Evaxion and no change to its cash runway through 2027.
2025-12-20 01:43
Reported Saturday, Evaxion Announces EVX-04 Triggers Specific Immune Responses Across 16 Selected ERV Fragments And Supports Broad Tumor Coverage For Acute Myeloid Leukemia
Designed with our proprietary AI-Immunology™ platform based on patient sequencing data, EVX-04 targets multiple non-conventional endogenous retrovirus (ERV) tumor antigensEVX-04 induces targeted immune responses
2025-12-08 16:49
Evaxion Advances Multi-Component Cytomegalovirus Vaccine Program, EVX-V1, With New Data Demonstrating Protective Effects Of Lead Antigens
Evaxion's AI-Immunology™ platform has discovered novel CMV antigens that significantly reduce viral infection in preclinical models EVX-V1 is a next-generation, multi-component vaccine program combining these
2025-11-20 21:04
Evaxion Biotech Increases Share Capital Following Warrant Exercise
Evaxion Biotech ( ($EVAX) ) has shared an announcement. On November 4, 2025, Ev...
2025-11-19 00:27
